Vanguard Group Inc Sellas Life Sciences Group, Inc. Call Options Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SLS
# of Institutions
37Shares Held
4.38MCall Options Held
3.27MPut Options Held
56.3K-
Geode Capital Management, LLC Boston, MA517KShares$610,0690.0% of portfolio
-
Black Rock Inc. New York, NY430KShares$507,8340.0% of portfolio
-
Empery Asset Management, LP New York, NY308KShares$363,9893.71% of portfolio
-
Opus Capital Group, LLC226KShares$266,7980.04% of portfolio
-
Equitable Holdings, Inc. New York, NY210KShares$247,8000.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $24.3M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...